Site-Level Variation in and Practices Associated With Dabigatran Adherence

• Published in: JAMA : the journal of the American Medical Association Vol. 313; no. 14; pp. 1443 - 1450
• Main Authors: Shore, Supriya, Ho, P. Michael, Lambert-Kerzner, Anne, Glorioso, Thomas J, Carey, Evan P, Cunningham, Fran, Longo, Lisa, Jackevicius, Cynthia, Rose, Adam, Turakhia, Mintu P
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 14.04.2015
• Subjects: Aged; Anticoagulants; Antithrombins - therapeutic use; Atrial Fibrillation - drug therapy; Benzimidazoles - therapeutic use; beta-Alanine - analogs & derivatives; beta-Alanine - therapeutic use; Cardiac arrhythmia; Cardiology; Clinical outcomes; Cross-Sectional Studies; Dabigatran; Drug Monitoring; Female; Hospitals, Veterans; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Selection; Pharmacists; Retrospective Studies; United States; United States
• ISSN: 0098-7484; 1538-3598
• DOI: 10.1001/jama.2015.2761

IMPORTANCE: Unlike warfarin, which requires routine laboratory testing and dose adjustment, target-specific oral anticoagulants like dabigatran do not. However, optimal follow-up infrastructure and modifiable site-level factors associated with improved adherence to dabigatran are unknown. OBJECTIVES: To assess site-level variation in dabigatran adherence and to identify site-level practices associated with higher dabigatran adherence. DESIGN, SETTING, AND PARTICIPANTS: Mixed-methods study involving retrospective quantitative and cross-sectional qualitative data. A total of 67 Veterans Health Administration sites with 20 or more patients filling dabigatran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total patients; median, 51 patients per site). Forty-seven pharmacists from 41 eligible sites participated in the qualitative inquiry. EXPOSURE: Site-level practices identified included appropriate patient selection, pharmacist-driven patient education, and pharmacist-led adverse event and adherence monitoring. MAIN OUTCOMES AND MEASURES: Dabigatran adherence (intensity of drug use during therapy) defined by proportion of days covered (ratio of days supplied by prescription to follow-up duration) of 80% or more. RESULTS: The median proportion of patients adherent to dabigatran was 74% (interquartile range [IQR], 66%-80%). After multivariable adjustment, dabigatran adherence across sites varied by a median odds ratio of 1.57. Review of practices across participating sites showed that appropriate patient selection was performed at 31 sites, pharmacist-led education was provided at 30 sites, and pharmacist-led monitoring at 28 sites. The proportion of adherent patients was higher at sites performing appropriate selection (75% vs 69%), education (76% vs 66%), and monitoring (77% vs 65%). Following multivariable adjustment, association between pharmacist-led education and dabigatran adherence was not statistically significant (relative risk [RR], 0.94; 95% CI, 0.83-1.06). Appropriate patient selection (RR, 1.14; 95% CI, 1.05-1.25), and provision of pharmacist-led monitoring (RR, 1.25; 95% CI, 1.11–1.41) were associated with better patient adherence. Additionally, longer duration of monitoring and providing more intensive care to nonadherent patients in collaboration with the clinician improved adherence. CONCLUSIONS AND RELEVANCE: Among nonvalvular atrial fibrillation patients treated with dabigatran, there was variability in patient medication adherence across Veterans Health Administration sites. Specific pharmacist-based activities were associated with greater patient adherence to dabigatran.